EnMed Collaboration Addresses Shortage of Inhaler Device to Help COVID-19 Patients | Houston Methodist
Asthma & COPD: COVID-19 Myth Busting with Dr. Juanita Mora | American Lung Association
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial - The Lancet Respiratory Medicine
COVID-19 causing inhaler shortage for asthmatics: experts | Miami Herald
What People With Asthma Should Know About COVID-19 - Keck Medicine of USC
Risk of severe COVID-19 from asthma and other respiratory diseases may be only modestly increased, new analysis suggests — Nuffield Department of Primary Care Health Sciences, University of Oxford
Coronavirus (COVID-19): What People With Asthma Need to Know | Asthma and Allergy Foundation of America
Managing adult asthma during the COVID-19 pandemic: A 2022 review and current recommendations - Annals Singapore
Coronavirus (COVID-19): What People With Asthma Need to Know | Asthma and Allergy Foundation of America
New VENTOLIN inhalers with dose counter reimbursed on the PBS for Australians - Asthma Australia
Medications in Coronavirus – Myths and Facts | Dyfi Valley Health
A message to asthma sufferers about a shortage of albuterol metered dose inhalers - ACAAI Public Website
Paracetamol and Ventolin limited to one per customer as Australia combats coronavirus hoarding | Coronavirus | The Guardian
Purchase limits for Ventolin, paracetamol | The Canberra Times | Canberra, ACT
Albuterol: Minimize COVID-19 spread without compromising patient care
Medicine used to treat asthma in high demand among COVID-19 patients | KFOX
Sterilization plan of the used metered dose inhalers (MDI) to avoid wastage amid COVID-19 pandemic drug shortage | Journal of Pharmaceutical Policy and Practice | Full Text
Naval Hospital Yokosuka - Effective immediately there will be temporary quantity limits on Albuterol inhalers distributed by USNHY affiliated pharmacies. These quantity limits ensure the even distribution of inhalers to treat existing
Biomolecules | Free Full-Text | Attacking COVID-19 Progression Using Multi-Drug Therapy for Synergetic Target Engagement
